Based on 2022 guidelines from the American Society of Clinical Oncology, the decision to initiate anti-EGFR treatment should be guided by the primary tumor location and testing for BRAF and RAS (KRAS and NRAS) mutations and deficient mismatch repair or MSI2. This evidence concerns the gene KRAS and neoplasm.